Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Chemomab Therapeutics Ltd ADR (CMMB)

Chemomab Therapeutics Ltd ADR (CMMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology GlobeNewswire - Tue Dec 2, 7:00AM CST

— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration...

CMMB : 1.8000 (-4.26%)
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit GlobeNewswire - Mon Nov 24, 7:00AM CST

TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

CMMB : 1.8000 (-4.26%)
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis GlobeNewswire - Thu Nov 6, 7:00AM CST

— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data...

CMMB : 1.8000 (-4.26%)
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire - Thu Aug 21, 7:00AM CDT

TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

CMMB : 1.8000 (-4.26%)
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Thu Aug 14, 7:00AM CDT

— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug’s...

CMMB : 1.8000 (-4.26%)
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25 GlobeNewswire - Mon Jun 30, 7:00AM CDT

CMMB : 1.8000 (-4.26%)
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis GlobeNewswire - Wed Jun 11, 7:00AM CDT

CMMB : 1.8000 (-4.26%)
KURA Stock Rises More Than 15% This Past Week: Here's Why
KURA Stock Rises More Than 15% This Past Week: Here's Why Zacks Investment Research - Fri Jun 6, 12:10PM CDT

Shares of Kura Oncology KURA have rallied 15.5% in the past week against the industry’s decline of 0.1%. Earlier this week, the FDA accepted the company’s new drug application (NDA) seeking full approval...

CMMB : 1.8000 (-4.26%)
LXRX : 1.2300 (unch)
AMRN : 14.14 (+3.21%)
KURA : 10.63 (-3.89%)
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis GlobeNewswire - Tue Jun 3, 7:00AM CDT

CMMB : 1.8000 (-4.26%)
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer Zacks Investment Research - Thu May 29, 10:50AM CDT

Candel Therapeutics CADL announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational adenovirus immunotherapy candidate, CAN-2409 (aglatimagene...

CMMB : 1.8000 (-4.26%)
LXRX : 1.2300 (unch)
AMRN : 14.14 (+3.21%)
CADL : 6.01 (-1.15%)

Barchart Exclusives

High Yield Meets High Conviction: 3 Dividend Stocks Built for Any Market Barchart - Fri Dec 26, 6:00PM CST
These stocks offer dividend growth, fair payout ratios, and analyst buy ratings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot